The Insider Selling: Illumina Inc. (ILMN) Director Sold $81804.00 in Stock

Regolare Commento Stampare

In a report released on Wednesday January 18, 2017 Deutsche Bank increased the stock price target of Illumina (NASDAQ:ILMN) to $160.00 indicating a possible downside of 0.00%. Morgan Stanley cut their target price on shares of Illumina from $115.00 to $100.00 and set an "underweight" rating on the stock in a research report on Wednesday, December 7th. Barclays PLC set a $142.00 price objective on shares of Illumina and gave the company an equal weight rating in a report on Tuesday, October 11th. The firm has a 50-day moving average of $134.52 and a 200-day moving average of $151.55. Post opening the session at $162.87, the shares hit an intraday low of $162.09 and an intraday high of $165 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Illumina Inc has 146,899,000 shares which are now outstanding with a price of 161.23 calculating Illumina Inc's market capitalisation to 23.68B Dollars. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have issued a buy rating to the company's stock. The life sciences company reported $0.97 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.87 by $0.10. Illumina had a net margin of 18.72% and a return on equity of 23.76%. The company presently has an average rating of "Hold" and an average target price of $152.88. The business earned $607 million during the quarter, compared to the consensus estimate of $628.06 million. Illumina's revenue for the quarter was up 10.4% compared to the same quarter previous year. During the same quarter previous year, the firm posted $0.80 EPS. Analysts forecast that Illumina will post $3.32 earnings per share for the current year. If you are reading this report on another website, it was stolen and republished in violation of USA & worldwide copyright legislation. The legal version of this article can be read at http://www.mareainformativa.com/illuminas-ilmn-neutral-rating-reiterated-at-robert-w-baird/94744/. Alps Advisors Inc. now owns 3,566 shares of the life sciences company's stock worth $501,000 after buying an additional 720 shares in the last quarter. LLC now owns 600 shares of the life sciences company's stock valued at $109,000 after buying an additional 560 shares during the last quarter. Following the completion of the transaction, the director now owns 17,065 shares of the company's stock, valued at approximately $2,303,945.65. Northwestern Mutual Wealth Management Co. boosted its stake in Illumina by 25.0% in the second quarter. On Dec 19, 2016, Omead Ostadan (EVP Ops, Products, Strategy) sold 2,000 shares at $126.16 per share price, according to the Form-4 filing with the securities and exchange commission. Shell Asset Management Co. now owns 28,670 shares of the life sciences company's stock worth $4,025,000 after buying an additional 3,201 shares in the last quarter. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. The disclosure for this sale can be found here. Mn Services Vermogensbeheer B.V. increased its position in Illumina by 2.0% in the third quarter. Cullen Frost Bankers Inc. now owns 6,770 shares of the life sciences company's stock worth $951,000 after buying an additional 75 shares in the last quarter. Diversified Trust Co now owns 6,125 shares of the life sciences company's stock worth $860,000 after buying an additional 550 shares in the last quarter. Retirement Systems of Alabama raised its position in shares of Illumina by 1.6% in the second quarter. Finally, Halsey Associates Inc. Diversified Trust Co raised its position in shares of Illumina by 9.9% in the second quarter.

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.